The Prevention of Dementia With Antihypertensive Treatment: New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study | Dementia and Cognitive Impairment | JAMA Internal Medicine | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.100.128. Please contact the publisher to request reinstatement.
1.
Rigaud  ASSeux  MLStaessen  JABirkenhäger  WHForette  F Cerebral complications of hypertension.  J Hum Hypertens. 2000;14605- 616Google ScholarCrossref
2.
Birkenhäger  WHForette  FSeux  MLWang  JGStaessen  JA Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension.  Arch Intern Med. 2001;161152- 156Google ScholarCrossref
3.
Fratiglioni  LDe Ronchi  DAgüero-Torres  H Worldwide prevalence and incidence of dementia.  Drugs Aging. 1999;15365- 375Google ScholarCrossref
4.
Forette  FSeux  MLStaessen  JA  et al.  Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.  Lancet. 1998;3521347- 1351Google ScholarCrossref
5.
Collins  RMacMahon  S Reliable assessment of the effects of treatment on mortality and major morbidity, I: clinical trials.  Lancet. 2001;357373- 380Google ScholarCrossref
6.
Staessen  JAFagard  RThijs  L  et al.  Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension.  Lancet. 1997;350757- 764Google ScholarCrossref
7.
Gasowski  JStaessen  JACelis  H  et al.  Systolic Hypertension in Europe (Syst-Eur) trial phase 2: objectives, protocol and initial progress.  J Hum Hypertens. 1999;13135- 145Google ScholarCrossref
8.
Forette  FAmery  AStaessen  J  et al.  Is prevention of vascular dementia possible? the Syst-Eur Vascular Dementia Project.  Aging (Milano). 1991;3373- 382Google Scholar
9.
Amery  ABirkenhäger  WBulpitt  CJ  et al.  Syst-Eur: a multicentre trial on the treatment of isolated systolic hypertension in the elderly: objectives, protocol, and organization.  Aging (Milano). 1991;3287- 302Google Scholar
10.
Folstein  MFFolstein  SEMcHugh  PR "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician.  J Psychiatr Res. 1975;12189- 198Google ScholarCrossref
11.
Gagnon  MLetenneur  LDartigues  JF  et al.  The validity of the Mini-Mental State Examination as a screening instrument for cognitive impairment and dementia in French elderly community residents.  Neuroepidemiology. 1990;9143- 150Google ScholarCrossref
12.
American Psychiatric Association, Diagnostic and Statistical Manual of Mental Disorders, Revised Third Edition.  Washington, DC American Psychiatric Association1987;
13.
Launer  LJ Overview of incidence studies of dementia conducted in Europe.  Neuroepidemiology. 1992;11 (suppl 1) 2- 13Google ScholarCrossref
14.
Loeb  CGandolfo  C Diagnostic evaluation of degenerative and vascular dementia.  Stroke. 1983;14399- 401Google ScholarCrossref
15.
Hachinski  VCLliff  LDZilkha  E  et al.  Cerebral blood flow in dementia.  Arch Neurol. 1975;32632- 637Google ScholarCrossref
16.
Katz  SFord  ABMoskowitz  RWJackson  BAJaffe  MW Studies of illness in the aged.  JAMA. 1963;185914- 919Google ScholarCrossref
17.
Hofman  AOtt  ABreteler  MMB  et al.  Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study.  Lancet. 1997;349151- 154Google ScholarCrossref
18.
Breteler  MMBClaus  JJGrobbee  DEHofman  A Cardiovascular disease and distribution of cognitive function in elderly people: the Rotterdam study.  BMJ. 1994;3081604- 1608Google ScholarCrossref
19.
Launer  LJWebster Ross  GPetrovitch  H  et al.  Midlife blood pressure and dementia: the Honolulu-Asia Aging Study.  Neurobiol Aging. 2000;2149- 55Google ScholarCrossref
20.
Prince  MCullen  MMann  A Risk factors for Alzheimer's disease and dementia: a case-control study based on the MRC elderly hypertension trial.  Neurology. 1994;4497- 104Google ScholarCrossref
21.
Breteler  MMB Vascular risk factors for Alzheimer's disease: an epidemiologic perspective.  Neurobiol Aging. 2000;21153- 160Google ScholarCrossref
22.
Pasquier  FLeys  D Why are stroke patients prone to develop dementia?  J Neurol. 1997;244135- 142Google ScholarCrossref
23.
Skoog  IMarcusson  JBlennow  K It's getting better all the time.  Lancet. 1998;352 (suppl 4) SIV4Google ScholarCrossref
24.
Hachinski  V Vascular dementia: the need for a new approach.  J Intern Med. 1997;242277- 279Google ScholarCrossref
25.
Andersen  KLauner  LJDewey  ME  et al.  Gender differences in the incidence of AD and vascular dementia: the EURODEM Studies.  Neurology. 1999;531992- 1997Google ScholarCrossref
26.
Skoog  INilsson  LPalmertz  BAndreasson  LASvanborg  A A population-based study of dementia in 85-year-olds.  N Engl J Med. 1993;328153- 158Google ScholarCrossref
27.
Ruitenberg  AOtt  Avan Swieten  JCHofman  ABreteler  MB Incidence of dementia: does gender make a difference?  Neurobiol Aging. 2001;22575- 580Google ScholarCrossref
28.
Guo  ZFratiglioni  LZhu  LFastbom  JWinblad  BViitanen  M Occurrence and progression of dementia in a community population aged 75 years and older: relationship with medication use.  Arch Neurol. 1999;56991- 996Google ScholarCrossref
29.
Tzourio  CDufouil  CDucimetière  PAlpérovitch  Afor the EVA Study Group, Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly.  Neurology. 1999;531948- 1952Google ScholarCrossref
30.
in't Veld  BARuitenberg  AHofman  AStricker  BHBreteler  MM Antihypertensive drugs and incidence of dementia: the Rotterdam Study.  Neurobiol Aging. 2001;22407- 412Google ScholarCrossref
31.
SHEP Cooperative Research Group, Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP).  JAMA. 1991;2653255- 3264Google ScholarCrossref
32.
Prince  MJBird  ASBlizard  RAMann  AH Is the cognitive function of older patients affected by antihypertensive treatment? results from 54 months of the Medical Research Council's treatment trial of hypertension in older adults.  BMJ. 1996;312801- 805Google ScholarCrossref
33.
Staessen  JAGasowski  JWang  JG  et al.  Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials.  Lancet. 2000;355865- 872Google ScholarCrossref
34.
Medical Research Council Working Party, Medical Research Council trial of treatment of hypertension in older adults: principal results.  BMJ. 1992;304405- 412Google ScholarCrossref
35.
PROGRESS Collaborative Group, Randomised trial of a perindopril-based blood pressure lowering regimen among 6105 individuals with prior stroke or transient ischaemic attack.  Lancet. 2001;3581033- 1041Google ScholarCrossref
36.
PROGRESS Management Committee, PROGRESS—Perindopril Protection Against Recurrent Stroke Study: characteristics of the study population at baseline.  J Hypertens. 1999;171647- 1655Google Scholar
37.
Di Bari  MPahor  MFranse  LV  et al.  Dementia and disability outcomes in large hypertension trials: lessons learned from the Systolic Hypertension in the Elderly Program (SHEP) trial.  Am J Epidemiol. 2001;15372- 78Google ScholarCrossref
38.
Morich  FJBieber  FLewis  JM  et al.  Nimodipine in the treatment of probable Alzheimer's disease: result of two multicentre trials.  Clin Drug Invest. 1996;11185- 195Google ScholarCrossref
39.
Parneti  LSenin  UMecocci  P Cognitive enhancement therapy for Alzheimer's disease: the way forward.  Drugs. 1997;53752- 768Google ScholarCrossref
40.
Mason  RPLeeds  PRJacob  RF  et al.  Inhibition of excessive neuronal apoptosis by the calcium antagonist amlodipine and antioxidants in cerebellar granule cells.  J Neurochem. 1999;721448- 1456Google ScholarCrossref
41.
Amenta  FStrocchi  PSabbatini  M Vascular and neuronal hypertensive brain damage: protective effect of treatment with nicardipine.  J Hypertens Suppl. 1996;14S29- S35Google ScholarCrossref
42.
Zipfel  GJLee  JMChoi  DW Reducing calcium overload in the ischemic brain.  N Engl J Med. 1999;3411543- 1544Google ScholarCrossref
43.
Pascale  AEtcheberrigaray  R Calcium alterations in Alzheimer's disease: pathophysiology, models and therapeutic opportunities.  Pharmacol Res. 1999;3981- 88Google ScholarCrossref
44.
Thibault  OPorter  NMChen  KC Calcium dysregulation in neuronal aging and Alzheimer's disease: history and new directions.  Cell Calcium. 1998;24417- 433Google ScholarCrossref
45.
Hong  YL The relationship between calcium antagonist–induced hypotension and central monoaminergic system in spontaneously hypertensive rats.  Int J Clin Pharmacol Ther Toxicol. 1987;25589- 597Google Scholar
46.
Murzenok  PPHuang  BSLeenen  FHH Sympathoinhibition by central and peripheral infusion of nifedipine in spontaneously hypertensive rats.  Hypertension. 2000;35631- 636Google ScholarCrossref
47.
Gould  RJMurphy  KMMSnyder  SH Autoradiographic localization of calcium channel antagonist receptors in rat brain with [3H]nitrendipine.  Brain Res. 1985;330217- 223Google ScholarCrossref
48.
Letenneur  LCommenges  RDDartigues  JFBarberger-Gateau  P Incidence of dementia and Alzheimer's disease in elderly community residents of south-western France.  Int J Epidemiol. 1994;231256- 1261Google ScholarCrossref
49.
Ott  ABreteler  MMBvan Harskamp  FGrobbee  DEHofman  A The incidence of dementia in the Rotterdam study. Iqbal  KWinblad  BNishimura  TTakeda  KWinieski  Heds. Alzheimer's Disease Biology, Diagnosis and Therapeutics. New York, NY John Wiley & Sons1997;1- 10Google Scholar
50.
Blood Pressure Lowering Treatment Trialists' Collaboration, Effect of ACE inhibitors, calcium antagonists, and other blood pressure-lowering drugs: results of prospectively designed overviews of randomised trials.  Lancet. 2000;3551955- 1964Google ScholarCrossref
51.
Staessen  JAWang  JGThijs  L Cardiovascular prevention and blood pressure reduction: a meta-analysis.  Lancet. 2001;3581305- 1315Google ScholarCrossref
52.
The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI).  Arch Intern Med. 1997;1572413- 2446Google ScholarCrossref
53.
Pahor  MPsaty  BMAlderman  MH  et al.  Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies.  Lancet. 2000;3561949- 1954Google ScholarCrossref
54.
Maxwell  CJHogan  DBEbly  EM Calcium-channel blockers and cognitive function in elderly people: results from the Canadian Study of Health and Aging.  CMAJ. 1999;161501- 506Google Scholar
Original Investigation
October 14, 2002

The Prevention of Dementia With Antihypertensive Treatment: New Evidence From the Systolic Hypertension in Europe (Syst-Eur) Study

Author Affiliations

From the Department of Geriatrics, Hôpital Broca, University of Paris V, Paris, France (Drs Forette and Seux); Study Coordinating Centre, Department of Molecular and Cardiovascular Research, University of Leuven, Leuven, Belgium (Drs Staessen and Fagard and Ms Thijs); Institute of Cardiology, Kaunas, Lithuania (Dr Babarskiene); National Institute Ana Aslan, Bucharest, Romania (Dr Babeanu); Centro Ipertensione Policlinico Umberto I, Rome, Italy (Dr Bossini); Facultad de Medicina, Universidad de Granada, Granada, Spain (Dr Gil-Extremera); Tallinn Central Hospital, Tallinn, Estonia (Dr Laks); Department of Internal Diseases, Municipal Clinical Hospital, Moscow, Russian Federation (Dr Kobalava); Department of Epidemiology and Health Promotion, National Public Health Institute, and Department of Public Health, University of Helsinki, Helsinki, Finland (Drs Sarti and Tuomilehto); Department of Medicine, Helsinki University Central Hospital, Helsinki, Finland (Dr Vanhanen); Aberdeen Royal Hospitals, University of Aberdeen, Aberdeen, Scotland (Dr Webster); Department of Family Medicine, Hadassah Medical School, Hebrew University of Jerusalem, Jerusalem, Israel (Dr Yodfat); and Erasmus University, Rotterdam, the Netherlands (Dr Birkenhäger).

Arch Intern Med. 2002;162(18):2046-2052. doi:10.1001/archinte.162.18.2046
Abstract

Background  After the double-blind, placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial ended in February 1997, randomized patients were offered active study medication for a further period of observation.

Objective  To refine the estimates of the long-term effects of antihypertensive therapy on the incidence of dementia.

Methods  Eligible patients had no dementia and were at least 60 years old. Their systolic blood pressure at entry was 160 to 219 mm Hg, with diastolic blood pressure below 95 mm Hg. Antihypertensive therapy was started immediately after randomization in the active treatment group, but only after termination of the double-blind trial in the control patients. Treatment consisted of nitrendipine (10-40 mg/d), with the possible addition of enalapril maleate (5-20 mg/d), hydrochlorothiazide (12.5-25 mg/d), or both add-on drugs.

Results  Median follow-up increased from 2.0 years in the double-blind trial to 3.9 years overall. The incidence of dementia doubled from 32 to 64 cases, 41 of whom had Alzheimer disease. Throughout follow-up, systolic/diastolic blood pressure was 7.0/3.2 mm Hg higher in the 1417 control patients than in the 1485 subjects randomized to active treatment. At the last examination, the blood pressure difference was still 4.2/2.9 mm Hg; 48.1%, 26.4%, and 11.4% of the control patients were taking nitrendipine, enalapril, and/or hydrochlorothiazide, whereas in the active treatment group these proportions were 70.2%, 35.4%, and 18.4%, respectively. Compared with the controls, long-term antihypertensive therapy reduced the risk of dementia by 55%, from 7.4 to 3.3 cases per 1000 patient-years (43 vs 21 cases, P<.001). After adjustment for sex, age, education, and entry blood pressure, the relative hazard rate associated with the use of nitrendipine was 0.38 (95% confidence interval, 0.23-0.64; P<.001). Treatment of 1000 patients for 5 years can prevent 20 cases of dementia (95% confidence interval, 7-33).

Conclusion  The extended follow-up of Syst-Eur patients reinforces the evidence that blood pressure–lowering therapy initiated with a long-acting dihydropyridine protects against dementia in older patients with systolic hypertension.

×